Cargando…
1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use
BACKGROUND: We implemented an Intravenous Antibiotics and Addiction Team (IVAT) intervention to identify hospitalized persons with a history of injection drug use (IDU) that are safe for discharge with IV antibiotics based on a 9-point risk assessment. IVAT has been shown to reduce average length of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252732/ http://dx.doi.org/10.1093/ofid/ofy209.104 |
_version_ | 1783373331656867840 |
---|---|
author | Eaton, Ellen Mathews, Ronald Lane, Peter S Paddock, Cayce S Rodriguez, J Martin Taylor, Benjamin B Saag, Michael Kilgore, Meredith Lee, Rachael |
author_facet | Eaton, Ellen Mathews, Ronald Lane, Peter S Paddock, Cayce S Rodriguez, J Martin Taylor, Benjamin B Saag, Michael Kilgore, Meredith Lee, Rachael |
author_sort | Eaton, Ellen |
collection | PubMed |
description | BACKGROUND: We implemented an Intravenous Antibiotics and Addiction Team (IVAT) intervention to identify hospitalized persons with a history of injection drug use (IDU) that are safe for discharge with IV antibiotics based on a 9-point risk assessment. IVAT has been shown to reduce average length of stay (ALOS) without increasing readmissions. We analyzed the cost savings of the IVAT to the health system. METHODS: PWID at the University of Alabama at Birmingham (UAB) hospital with indications for prolonged IV antibiotics received IVAT to determine risk of continued IDU. “Low-risk” patients were discharged for outpatient antibiotics and addiction care; others continued inpatient antibiotics, group therapy, opioid agonist therapy (if applicable), and weekly assessment for discharge readiness. Cost of care was defined by direct costs and was obtained by querying financial accounts. RESULTS: A total of 37 pre-IVAT and 111 post-IVAT admissions (including 25 “low risk”) met study criteria. IVAT reduced ALOS by 20 days. Total direct costs per admission in the post-IVAT period were 33% lower: $26,014 versus $38,716 (Table 1). Because ALOS at UAB for all patients is 6.58 days, a 20-day ALOS reduction following IVAT creates capacity for an additional 333 patients (n = 20/6.58 × 111). CONCLUSION: IVAT for PWID allows health systems to focus inpatient resources on those at greatest risk of ongoing IVDU, creates additional inpatient capacity, and may cut hospital direct costs by one-third. DISCLOSURES: J. M. Rodriguez, finch: Research Contractor, Research support. seres: Research Contractor, Research support. |
format | Online Article Text |
id | pubmed-6252732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62527322018-11-28 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use Eaton, Ellen Mathews, Ronald Lane, Peter S Paddock, Cayce S Rodriguez, J Martin Taylor, Benjamin B Saag, Michael Kilgore, Meredith Lee, Rachael Open Forum Infect Dis Abstracts BACKGROUND: We implemented an Intravenous Antibiotics and Addiction Team (IVAT) intervention to identify hospitalized persons with a history of injection drug use (IDU) that are safe for discharge with IV antibiotics based on a 9-point risk assessment. IVAT has been shown to reduce average length of stay (ALOS) without increasing readmissions. We analyzed the cost savings of the IVAT to the health system. METHODS: PWID at the University of Alabama at Birmingham (UAB) hospital with indications for prolonged IV antibiotics received IVAT to determine risk of continued IDU. “Low-risk” patients were discharged for outpatient antibiotics and addiction care; others continued inpatient antibiotics, group therapy, opioid agonist therapy (if applicable), and weekly assessment for discharge readiness. Cost of care was defined by direct costs and was obtained by querying financial accounts. RESULTS: A total of 37 pre-IVAT and 111 post-IVAT admissions (including 25 “low risk”) met study criteria. IVAT reduced ALOS by 20 days. Total direct costs per admission in the post-IVAT period were 33% lower: $26,014 versus $38,716 (Table 1). Because ALOS at UAB for all patients is 6.58 days, a 20-day ALOS reduction following IVAT creates capacity for an additional 333 patients (n = 20/6.58 × 111). CONCLUSION: IVAT for PWID allows health systems to focus inpatient resources on those at greatest risk of ongoing IVDU, creates additional inpatient capacity, and may cut hospital direct costs by one-third. DISCLOSURES: J. M. Rodriguez, finch: Research Contractor, Research support. seres: Research Contractor, Research support. Oxford University Press 2018-11-26 /pmc/articles/PMC6252732/ http://dx.doi.org/10.1093/ofid/ofy209.104 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Eaton, Ellen Mathews, Ronald Lane, Peter S Paddock, Cayce S Rodriguez, J Martin Taylor, Benjamin B Saag, Michael Kilgore, Meredith Lee, Rachael 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use |
title | 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use |
title_full | 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use |
title_fullStr | 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use |
title_full_unstemmed | 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use |
title_short | 1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use |
title_sort | 1634. a 9-point risk assessment for patients who inject drugs requiring intravenous antibiotics may allow health systems to focus inpatient resources on those at greatest risk of ongoing drug use |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252732/ http://dx.doi.org/10.1093/ofid/ofy209.104 |
work_keys_str_mv | AT eatonellen 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse AT mathewsronald 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse AT lanepeters 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse AT paddockcayces 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse AT rodriguezjmartin 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse AT taylorbenjaminb 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse AT saagmichael 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse AT kilgoremeredith 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse AT leerachael 1634a9pointriskassessmentforpatientswhoinjectdrugsrequiringintravenousantibioticsmayallowhealthsystemstofocusinpatientresourcesonthoseatgreatestriskofongoingdruguse |